Copyright
©The Author(s) 2020.
World J Transplant. Jan 18, 2020; 10(1): 15-28
Published online Jan 18, 2020. doi: 10.5500/wjt.v10.i1.15
Published online Jan 18, 2020. doi: 10.5500/wjt.v10.i1.15
Table 1 Outcomes from meta-analyses or large studies comparing donation after circulatory death to donation after brain death outcomes in abdominal organ transplantation
DCD | DBD | P value | |
Kidney[56] | |||
PNF (%) | 3.2 | 2.6 | 0.06 |
DGF (%) | 48.5 | 24.9 | < 0.001a |
1-yr eGFR1 | 47.4 (35.6-61.2) | 48.7 (37.3-61.1) | 0.69 |
5-yr graft survival (%) | 76.8 | 78.1 | 0.60 |
5-yr patient survival (%) | 86.5 | 89.4 | < 0.001a |
Liver[57] | |||
Biliary complications (%) | 26 | 16 | < 0.001a |
Ischemic cholangiopathy (%) | 16 | 3 | < 0.001a |
3-yr graft survival (%) | 73 | 74 | 0.01a |
3-yr patient survival (%) | 82 | 88 | 0.04a |
Pancreas[7] | |||
Graft survival | HR 0.98 (0.74-1.31) | Reference value | 0.92 |
Patient survival | HR 1.31 (0.62-2.78) | Reference value | 0.47 |
Graft thrombosis | OR 1.67 (1.04-2.67) | Reference value | 0.006a |
Table 2 Clinical studies published about kidney transplant outcomes after abdominal regional perfusion
Graft survival, % | Patient survival, % | ||||||||||
Study | n | DCD type | Rejection, % | DGF, % | PNF, % | 1 | 3 | 5 | 1 | 3 | 5 |
HRP | |||||||||||
Valero et al[35], 2000 | 8 | II | - | 75 | 0 | - | - | - | - | - | - |
Koyama et al[58], 2002 | 46 | III/IV | - | 87 | 6.5 | 88.3 | - | - | - | - | - |
Lee et al[34], 2005 | 31 | II/III/IV | 35.5 | 41.9 | 0 | 100 | - | 88.4 | 100 | - | 100 |
Sánchez-Fructuoso et al[59], 2006 | 320 | I/II | 4.4 | 60.9 | 4.4 | 87.4 | - | 82.1 | 95 | - | 90 |
Farney et al[33], 2011 | 25 | III | 16 | 21 | 0 | 88 | 88 | - | - | - | - |
NRP | |||||||||||
Valero et al[35], 2000 | 8 | II | - | 12.5 | 0 | - | - | - | - | - | - |
Magliocca et al[37], 2005 | 24 | III | 0 | 8.3 | 0 | - | - | - | - | - | - |
Reznik et al[60], 2011 | 20 | II | 10 | 70 | 10 | - | - | - | - | - | - |
Hessheimer et al[61], 2015 | 158 | II | - | 65 | 9 | 88 | - | - | - | - | - |
Oniscu et al[42], 2014 | 32 | III | - | 40 | 6 | 87.5 | - | - | 96.8 | - | - |
Butler et al[43], 2014 | 141 | III | - | 18.2 | 9.1 | - | - | - | - | - | - |
Rojas-Peña et al[62], 2014 | 292 | III | - | 31 | 3.5 | - | - | - | - | - | - |
Demiselle et al[63], 2016 | 19 | II | - | 53 | 5.3 | 94 | - | - | 100 | - | - |
Miñambres et al[36], 2017 | 37 | III | - | 27 | 5 | 91.8 | - | - | - | - | - |
Table 3 Clinical studies published about liver transplant outcomes after normothermic regional perfusion
Graft survival, % | Patient survival, % | |||||||||||
Study | n | DCD type | Rejection, % | BC, % | IC, % | PNF, % | 1 | 3 | 5 | 1 | 3 | 5 |
Otero et al[64], 2004 | 14 | II | 22 | - | 28 | 28 | 43 | - | - | 71 | - | - |
Fondevila et al[41], 2007 | 10 | II | - | 10 | - | 10 | 50 | - | - | 70 | - | - |
Jiménez-Galanes et al[65], 2009 | 20 | II | - | - | 5 | 10 | 80 | - | - | 85 | - | - |
Fondevila et al[66], 2012 | 34 | II | - | 12 | 8 | 4.3 | - | - | - | - | - | - |
Oniscu et al[42], 2014 | 11 | III | - | 18.2 | 0 | 9.1 | 87.5 | - | - | 96.8 | - | - |
Butler et al[43], 2014 | 3 | III | - | - | 0 | - | - | - | - | - | - | - |
Rojas-Peña et al[62], 2014 | 13 | III | - | - | 14.3 | 14.3 | 85.7 | - | - | - | - | - |
Hessheimer et al[61], 2015 | 42 | II | - | - | 10 | 73 | - | - | - | - | - | |
De Carlis et al[67], 2016 | 7 | II/III | 14.3 | 14.3 | 0 | 0 | - | - | - | - | - | - |
Miñambres et al[36], 2017 | 11 | III | - | 0 | 0 | 9.1 | 90.9 | - | - | - | - | - |
Hessheimer et al[40], 2019 | 95 | III | - | 8 | 2 | 2 | 88 | 88 | - | 93 | 93 | - |
Table 4 Currently ongoing clinical trials concerning ex vivo machine perfusion in kidney transplantation
Name of study | Registration number | Design | PI | n | Primary outcome | Intervention | Included donors | Results |
Unknown | ISRCTN91315246 | Non-randomized | Cambridge | 90 | Graft function | 1 h NMP | Discarded kidneys | November 2019 |
COPE-POMP | ISRCTN63852508 | RCT | COPE Essen | 262 | Graft survival 1y | Short period HMP vs SCS only | ECD-DBD | July 2019 |
COPE-COMPARE | ISRCTN32967929 | RCT | COPE Leuven | 162 | Kidney graft function 1 y | HMP with oxygen vs HMP without oxygen | DCD III | ↓ risk BPAR ↑ 1-y eGFR[44] |
PIO | NCT03031067 | Case control | Bologna | 20 | Graft function | 2 h HMP vs SCS | ECD -DBD | February 2018 |
PREDICTION | NCT02055950 | Case control | Bergamo | 60 | Kidney function | HMP vs SCS | ECD-DBD | Augustus 2018 |
Unknown | NCT03837197 | RCT | Bologna | 260 | DGF | 2 h oxygenated HMP vs SCS | ECD-DBD | December 2021 |
IMPULSION | NCT01170910 | RCT | Lyon | 162 | DGF | 6-8 h HMP vs SCS | ECD | August 2016 |
Machine perfusion trial | ISRCTN83876362 | RCT | COPE Groningen | 654 | DGF | Non-oxygenated HMP vs SCS | DCD III and DBD | ↓ risk of DGF (OR 0.57) ↓ risk of graft failure (HR 0.52) ↑ allograft survival (94 vs 90%, P = 0.04)[27] |
Unknown | ISRCTN15821205 | RCT | Cambridge | 400 | DGF | 1 h pre-transplant NMP vs SCS | DCD III and IV | January 2021 |
Table 5 Currently ongoing clinical trials concerning ex vivo machine perfusion in liver transplantation
Name of study | Design | PI | n | Primary outcome | Intervention | Included donors | Results | |
DHOPE DCD | NCT02584283 | RCT | Groningen | 156 | % NAS | 2 h end-ischemic DHOPE | DCD III | October 2019 |
HOPE | NCT01317342 | RCT | Zürich | 170 | Postoperative complications | 1-2 h HOPE | DBD | July 2019 |
HOPE ECD-DBD | NCT03124641 | RCT | Aachen | 46 | Peak ALT | 1-2 h HOPE | ECD-DBD | June 2019 |
DHOPE-COR-NMP | NTR5972 | Non-randomized | Groningen | 16 | Graft survival | DHOPE, gradually rewarming, NMP | Discarded livers (DCD and DBD) | 11 livers transplanted 100% patient/graft survival, 9.1% ischemic cholangiopathy[48] |
PIO | NCT03031067 | Case control | Bologna | 20 | Graft function | 2 h HOPE | ECD livers | February 2018 |
VITTAL | NCT02740608 | Non-randomized | Birmingham | 22 | Patient survival | 4 h NMP | Discarded livers (DCD and DBD) | March 2020 |
Liver WP2 | ISRCTN39731134 | RCT | Oxford COPE | 220 | Peak AST | Minimally 4 h NMP | All deceased donors | 49.4% ↓ peak AST[47] |
CORNET | ISRCTN94691167 | RCT | Essen | 40 | Peak AST | 1,5 h COR until 20 degrees (dual perfusion) | ECD | February 2021 |
DHOPE | NTR4493 | Case control | Groningen | 10 | Graft survival 6 mo | At least 2 h of DHOPE | DCD III | ↑ graft survival (P = 0.052) ↓peak ALT (P = 0.006) ↓bilirubin (P = 0.044)[46] |
Unknown | NCT03837197 | RCT | Bologna | 260 | Early allograft dysfunction | Minimally 1 hour of HOPE | ECD-DBD | December 2021 |
- Citation: Rijkse E, IJzermans JN, Minnee RC. Machine perfusion in abdominal organ transplantation: Current use in the Netherlands. World J Transplant 2020; 10(1): 15-28
- URL: https://www.wjgnet.com/2220-3230/full/v10/i1/15.htm
- DOI: https://dx.doi.org/10.5500/wjt.v10.i1.15